Bausch Health’s global eye health division, Bausch and Lomb, has signed an exclusive license to develop Brien Holden Vision Institute’s (BHVI) myopia control contact lens design.   

“We are excited to leverage cutting-edge contact lens design technology from renowned ophthalmic research organisation BHVI with our leading lens technologies, so that we can research potential new treatment options for myopia, which continues to become more prevalent around the world,” said Joseph Papa, CEO, Bausch Health.  

Saying it is committed to finding new approaches for myopia control, Bausch Health has also acquired an exclusive license from Eyenovia in the US and Canada for the development and commercialisation of an investigational microdose formulation of atropine, currently under investigation for the reduction of paediatric myopia progression in children ages 3-12.